4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004

Author's Avatar
Jan 20, 2022

4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that it will host a virtual Key Opinion Leader (KOL) event to review previously disclosed positive topline results from Part A of its Phase I/II trial of MRx-4DP0004 for the treatment of asthma and to discuss the asthma treatment landscape. The event will take place on Thursday, January 27, 2022, from 8:00 a.m. ET (1:00 p.m. GMT).